MAP2K7 and head and neck squamous cell carcinoma: This contrasted with the addition of other ErbB family ligands like neuregulin-1, which consistent with the lack of predictive power, did not alter the ability of SHP099 to block PI3K or MEK signaling or exert anti-HNSCC activity (Supplementary Fig. S8A and S8B).